# Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

> **NCT03386474** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 151 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Brolucizumab 6 mg
- **DRUG:** Aflibercept 2 mg

## Key facts

- **NCT ID:** NCT03386474
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-15
- **Primary completion:** 2018-09-06
- **Final completion:** 2018-09-06
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386474, "Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03386474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*